# Nuvectis Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuvectis-pharma

- Industry: Biotechnology
- Headquarters: Fort Lee, US
- Website: www.nuvectis.com
- Total disclosed funding: $15M
- Latest round: Series A (May 23, 2021)
- Investors on record: 1

## About

Based in New Jersey, US, and founded in 2020, Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. As of 2022, Ron Bentsur is the CEO of the company. In May 2021, Nuvectis Pharma, Inc. raised USD 15.3 million in Series A funding from Sixth Element Capital and other investors. The company is traded on the NASDAQ under the ticker symbol NVCT.

The company is developing a pipeline that includes two drug candidates, such as NXP800, which is an oral small molecule HSF-1 pathway inhibitor, and NXP900, which is an oral small molecule SRC/YES1 kinase inhibitor.

## Funding rounds

- Series A, May 23, 2021, $15M — Sixth Element Capital

## Investors

- Sixth Element Capital (https://capitalatlas.ai/funds/sixth-element-capital) — Series A